Mountain Group Capital

Mountain Group News

Latest News

G1 Therapeutics Initiates Three Drug Development Programs in Breast Cancer

Phase 2 trial of trilaciclib in triple-negative breast cancer Phase 1b/2a trial of G1T38 in estrogen receptor-positive breast cancer Oral SERD (G1T48) in IND-enabling studies; Phase 1 trial planned for 4Q17 RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2017 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the expansion of its pipeline of novel cancer therapies with the initiation of three development programs in breast cancer. G1…

G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer

Phase 2 study evaluating potential of Genentech’s Tecentriq plus trilaciclib and chemotherapy as a first-line treatment for small-cell lung cancer patients expected to begin in first half of 2017

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. a clinical-stage oncology company, announced today a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase 2 clinical trial is expected to begin in the first half of 2017 and will evaluate the combination of Genentech’s immune checkpoint, anti-PD-L1 antibody Tecentriq® (atezolizumab) with G1’s CDK4/6 inhibitor trilaciclib (G1T28) as a first-line treatment for…

AgTech Accelerator Corporation Announces the Addition of Animal Health Pioneer Elanco to Blue-Chip Investor Syndicate; Completes $20 Million First Closing

High Demand Enables AgTech Accelerator to Cultivate High-Value, Early-Stage, Commercially Viable Agricultural Technologies

RESEARCH TRIANGLE PARK, N.C. – November 2, 2016 – AgTech Accelerator™, a unique startup accelerator vehicle focused on discovering and developing emerging agricultural technology companies, today announced the closing of an additional $8.5 million in financing, nearly doubling its capital since the initial launch in May 2016. The additional financing brings its total capital commitments to $20 million. Elanco, a leader in developing products and knowledge services to improve animal…

NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis

NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, and One Way Liver S.L. (OWL Metabolomics), a leader in the field of metabolomics and liver diseases diagnostics, today announced they have initiated a strategic partnership to develop novel diagnostic tools for ongoing drug evaluation trials for NuSirt’s fatty liver drug research candidate, NS-0200. Through their research collaboration, NuSirt and OWL will evaluate drug-induced lipidomic…

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

ALPHARETTA, Ga., June 01, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of $7.00 per share.  In addition, Clearside has granted the underwriters a 30-day option to purchase up to an additional 1,080,000…

G1 Therapeutics Secures $47 Million Series C Financing

Proceeds will advance lead CDK4/6 inhibitors through early and mid-stage clinical trials, expand pipeline in multiple oncology indications

RESEARCH TRIANGLE PARK, N.C., May 11, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the completion of a $47 million Series C financing led by new investor Cormorant Asset Management. Additional new investors include Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments and Rock Springs Capital. All existing investors participated in the financing: Eshelman Ventures, Hatteras Venture Partners, Lumira Capital, MedImmune Ventures, Mountain Group…

Agriculture Start-Ups Get Boost From Big Firms and Investors

Compared with medicine, where small companies often lead in turning cutting-edge science into new drugs, agriculture has never had much start-up activity.

Mississippi Power, Silicon Ranch break ground on new solar energy facility

$100-million facility to generate enough electricity to power thousands of homes

Gulfport, Miss. – Mississippi Power and Silicon Ranch Corporation, along with local officials from the city of Hattiesburg, Forrest County and the Area Development Partnership, held a groundbreaking ceremony for the state’s largest solar farm today in Hattiesburg. When operational, the $100-million facility will generate 50 MW, enough electricity to supply power to approximately 6,500 homes. Members of the Mississippi Public Service Commission were also on hand for the ceremony,…

Partners Group invests USD 100 million in Silicon Ranch Corporation, a US developer, owner and operator of solar power production facilities

Partners Group, the global private markets investment manager, has agreed to provide USD 100 million in growth capital to Silicon Ranch Corporation (“Silicon Ranch”), a leading developer, owner and operator of solar energy facilities in the US, on behalf of its clients. The company’s existing investors will also participate in this corporate equity raise, which will support Silicon Ranch in building out its substantial portfolio of growth projects. With this…

Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion

Patients receiving a single treatment of ZUPRATA™ together with EYLEA® qualified for 60% fewer additional EYLEA retreatments over a 3-month period (p=0.013)

Patients in the ZUPRATA + EYLEA arm achieved 19 letters of improvement in Best Corrected Visual Acuity as compared to 11 letters of improvement following EYLEA-alone

Alpharetta, GA (April 26, 2016) – Clearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint.  In preliminary results from the trial, patients in the active arm (those receiving concomitant administration of ZUPRATA and EYLEA) qualified…

← Previous Page&mdashNext Page →